NASDAQ · NBIX
Neurocrine Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NBIX: Nov 02, 2026
Neurocrine Biosciences, Inc. Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.99. The reported EPS for the same quarter last year was $2.04.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.99 | $2.44 | $1.42 | 7 |
| Dec 2026 | $2.08 | $2.65 | $1.48 | 7 |
| Mar 2027 | $1.77 | $2.39 | $0.73 | 3 |
| Jun 2027 | $2.16 | $2.73 | $1.22 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · BNK Invest- Zacks · Oct 27, 9:00 AM EDTAmneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 26, 10:11 AM EDTNeurocrine Sets Benchmark For Measuring Health Improvements In Tardive Dyskinesia Patients(RTTNews) – Neurocrine Biosciences (NBIX) presented new research that establishes a benchmark for what constitutes a meaningful improvement in overall health for people living with tardive dyskinesia, a movement disorder characterized by involuntary and repetitive body movements.
- Zacks · Oct 26, 9:00 AM EDTNeurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Oct 25, 7:05 AM EDTWhere Will Neurocrine Biosciences Be in 5 Years?Ingrezza remains Neurocrine's biggest revenue driver, with sales growing 15%.
- RTTNews · Oct 16, 9:11 AM EDTNeurocrine Presents Real-World Data Mapping Evolving Impact Of Congenital Adrenal Hyperplasia(RTTNews) – Neurocrine Biosciences (NBIX) reported real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient's life. Patient records showed growth and bone-age monitori
- BNK Invest · Oct 14, 10:45 AM EDTNBIX October 2027 Options Begin TradingInvestors in Neurocrine Biosciences, Inc. (Symbol: NBIX) saw new options become available today, for the October 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 366 days until expiration the newly ava
- Zacks · Oct 14, 8:40 AM EDTWhy Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Oct 13, 10:40 AM EDTNBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?NBIX vs. SDZNY: Which Stock Is the Better Value Option?
- Zacks · Oct 13, 8:45 AM EDTWhy Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Oct 9, 9:28 AM EDT4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
- RTTNews · Sep 29, 3:50 AM EDTNeurocrine Biosciences Reappoints Eiry Roberts As CMO, Keswani Departs(RTTNews) – Neurocrine Biosciences, Inc. (NBIX) announced that Eiry W. Roberts will return as Chief Medical Officer, effective immediately, succeeding Sanjay Keswani, who will depart the company by mutual agreement.
- MarketBeat · Sep 23, 12:02 AM EDTNeurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingNeurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify b
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Neurocrine Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.